quinazolines has been researched along with clindamycin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Divo, AA; Geary, TG; Jensen, JB | 1 |
| Adams, D; Fernanadez, EM; Seiverling, EV | 1 |
| Altomare, G; Bidoli, P; Cazzaniga, ME; Cicchiello, F; Colombo, I; Cortinovis, DL; Crippa, A; Villa, F | 1 |
3 other study(ies) available for quinazolines and clindamycin
| Article | Year |
|---|---|
An in vitro assay system for the identification of potential antimalarial drugs.
Topics: Animals; Antimalarials; Cattle; Chloramphenicol; Chloroquine; Clindamycin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Erythrocytes; Humans; Hypoxanthine; Hypoxanthines; Piperidines; Plasmodium falciparum; Quinazolines; Quinazolinones; Rabbits | 1983 |
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Drug Eruptions; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Sulfacetamide; Triamcinolone | 2006 |
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Topics: Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Dermatologic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Isotretinoin; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |